Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2021-01-28 Capital/Financing Update
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement related to convertible note hedge transactions and amendments, as well as information about cash bonus payments approved for named executive officers. There is no comprehensive financial data or full financial statements presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document announces changes related to agreements and management compensation but does not detail board changes or full management structure updates, so it is not MANG. The focus on amendments to financing agreements and repurchases of notes indicates a Capital/Financing Update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2021-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.